Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Stored Tumor Samples in Young Patients With Brain Tumors

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2016 by St. Jude Children's Research Hospital
Sponsor:
Information provided by (Responsible Party):
St. Jude Children's Research Hospital
ClinicalTrials.gov Identifier:
NCT00897286
First received: May 9, 2009
Last updated: August 19, 2016
Last verified: August 2016

May 9, 2009
August 19, 2016
November 2004
February 2026   (final data collection date for primary outcome measure)
Relationship between molecular abnormalities and tumor histologic and clinical characteristics [ Time Frame: 20 Years ] [ Designated as safety issue: No ]
Relationship between molecular abnormalities and tumor histologic and clinical characteristics [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00897286 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study of Stored Tumor Samples in Young Patients With Brain Tumors
Molecular and Histopathologic Characterization of Atypical Teratoid Rhabdoid Tumors, Choroid Plexus Carcinomas, Ependymomas, Medulloblastoma/PNET and Gliomas of the Pediatric CNS
This laboratory study is looking at stored tumor samples in young patients with brain tumors. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
The overall objective of this non-therapeutic protocol is to identify molecular abnormalities within prospectively treated pediatric CNS develop xenograft and in vitro models derived from Atypical Teratoid Rhabdoid Tumors (ATRT), Choroid Plexus Carcinomas (CPC), Ependymoma and high-grade gliomas. The investigators will characterize the genome-wide mutation, expression and epigenetic signatures of these models and compare them with the primary tumors from which they were derived, thus creating well-characterized and invaluable resource for research on these rare and deadly pediatric brain tumors. This will also provide important insights into intratumoral heterogeneity, and molecular abnormalities that may influence the selective pressures driving evolution, and tumor growth as xenografts or in vitro. and define the relationship between these abnormalities and tumor histologic and clinical characteristics. This objective will be achieved by applying state-of-the-art DNA, RNA and protein epigenome analysis tools to the study of fresh frozen, fixed and cultured tumor cells and xenografts. The establishment of cell cultures from each tumor sample will also allow for in vitro and in vivo analysis of tumor cell growth, signaling and therapeutic response.
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:
Fresh frozen, fixed and cultured tumor cells collected prospectively from a clinically well characterized patient cohort.
Non-Probability Sample
Participants will have ATRT, CPC, medulloblastoma/PNET, ependymoma or glioma of the CNS as documented by the local neuropathologist. All studies will be conducted using tumor material collected prospectively from a clinically well characterized patient cohort.
Brain and Central Nervous System Tumors
Not Provided
Tumor/Tissue Sample
Tumor material collected prospectively from a clinically well characterized patient cohort
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
500
February 2026
February 2026   (final data collection date for primary outcome measure)

Inclusion Criteria

  • ATRT, CPC, medulloblastoma/PNET, ependymoma or glioma of the CNS as documented by the local neuropathologist. Tumor may be primary, progressive or recurrent CNS tumor including brain and/or spine. For fresh tissue, in some cases we must process the tissue before a final diagnosis is available. If a xenograft is established from a brain tumor that is later diagnosed to be a different histological subtype, we will store frozen viable cells for potential future use. Although rare, patients with ATRT may present with a primary renal and CNS tumor. In these instances samples will be collected from both the kidney and CNS tumor for analysis if available.
  • Tumor may be collected at surgery prior to histologic confirmation
  • Age not more than 21 years at the time of initial diagnosis.
  • Enrollment in the current version of the institution's banking protocol
  • Biological parent(s) of participant (child) whose tumor is studied on this protocol. These parents will be assigned to cohort P. The exclusion criteria below do not apply to this cohort.

Exclusion Criteria

  • Diagnosis of tumor outside the central nervous system.
  • Age greater than 21 years at the time of diagnosis
Both
up to 21 Years   (Child, Adult)
No
Contact: Tabatha E. Doyle, RN 901-595-2544 tabatha.doyle@stjude.org
United States
 
NCT00897286
NBTP01
No
Not Provided
Not Provided
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Not Provided
Principal Investigator: Amar Gajjar, MD St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
August 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP